Low-dose HDACi potentiates anti-tumor activity of macrophages in immunotherapy

The success of checkpoint immunotherapy has created optimism that cancer may be curable. However, not all patients respond, resistance is common and many patients relapse owing to immune escape. We demonstrate that HDAC inhibition not only decreases the trafficking of myeloid-derived suppressor cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xiaolei, Dai, Hanren, Wang, Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Author’s View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8183541/
https://www.ncbi.nlm.nih.gov/pubmed/34123577
http://dx.doi.org/10.1080/2162402X.2021.1935668
_version_ 1783704393868115968
author Li, Xiaolei
Dai, Hanren
Wang, Hua
author_facet Li, Xiaolei
Dai, Hanren
Wang, Hua
author_sort Li, Xiaolei
collection PubMed
description The success of checkpoint immunotherapy has created optimism that cancer may be curable. However, not all patients respond, resistance is common and many patients relapse owing to immune escape. We demonstrate that HDAC inhibition not only decreases the trafficking of myeloid-derived suppressor cells (MDSCs) into tumors but also potentiates tumor-associated macrophages (TAMs) to specify anti-tumoral phenotype and bolster T cells activation within the tumor microenvironment (TME).
format Online
Article
Text
id pubmed-8183541
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-81835412021-06-11 Low-dose HDACi potentiates anti-tumor activity of macrophages in immunotherapy Li, Xiaolei Dai, Hanren Wang, Hua Oncoimmunology Author’s View The success of checkpoint immunotherapy has created optimism that cancer may be curable. However, not all patients respond, resistance is common and many patients relapse owing to immune escape. We demonstrate that HDAC inhibition not only decreases the trafficking of myeloid-derived suppressor cells (MDSCs) into tumors but also potentiates tumor-associated macrophages (TAMs) to specify anti-tumoral phenotype and bolster T cells activation within the tumor microenvironment (TME). Taylor & Francis 2021-06-06 /pmc/articles/PMC8183541/ /pubmed/34123577 http://dx.doi.org/10.1080/2162402X.2021.1935668 Text en © 2021 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Author’s View
Li, Xiaolei
Dai, Hanren
Wang, Hua
Low-dose HDACi potentiates anti-tumor activity of macrophages in immunotherapy
title Low-dose HDACi potentiates anti-tumor activity of macrophages in immunotherapy
title_full Low-dose HDACi potentiates anti-tumor activity of macrophages in immunotherapy
title_fullStr Low-dose HDACi potentiates anti-tumor activity of macrophages in immunotherapy
title_full_unstemmed Low-dose HDACi potentiates anti-tumor activity of macrophages in immunotherapy
title_short Low-dose HDACi potentiates anti-tumor activity of macrophages in immunotherapy
title_sort low-dose hdaci potentiates anti-tumor activity of macrophages in immunotherapy
topic Author’s View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8183541/
https://www.ncbi.nlm.nih.gov/pubmed/34123577
http://dx.doi.org/10.1080/2162402X.2021.1935668
work_keys_str_mv AT lixiaolei lowdosehdacipotentiatesantitumoractivityofmacrophagesinimmunotherapy
AT daihanren lowdosehdacipotentiatesantitumoractivityofmacrophagesinimmunotherapy
AT wanghua lowdosehdacipotentiatesantitumoractivityofmacrophagesinimmunotherapy

Ejemplares similares